GLP-1 receptor agonists used for weight loss appear to cause modest reductions in bone mineral density and increase bone turnover, similar to what happens with calorie restriction alone.
7–10% weight lossThe threshold at which weight reduction — whether from calorie restriction, surgery, or medication — consistently leads to high-turnover bone loss
What the researchers found
In rodent models, liraglutide positively influenced bone material properties despite weight loss, but the most favorable effects on bone mineral density and microarchitecture occurred at doses much higher than those approved for human obesity treatment.
In humans with obesity, preliminary findings indicate GLP-1 receptor agonists cause modest bone mineral density reduction and enhance bone remodeling that favors resorption — a pattern similar to the effects seen with calorie restriction producing 7–10% weight loss. Significant weight reduction through calorie restriction or bariatric surgery consistently results in high-turnover bone loss.
Why it matters
With millions of people now using GLP-1 drugs for weight loss, understanding their bone health implications is critical — especially since significant weight loss from any cause is known to reduce bone density. This review helps clarify whether bone changes seen with these drugs are a direct drug effect or simply a consequence of losing weight.
How the study worked
This was a comprehensive literature review of preclinical studies and human data published in English from January 2013 to December 2024. The authors searched for studies examining the effects of GLP-1 receptor agonists on bone health, and also summarized data on bone outcomes from calorie restriction and bariatric surgery for context.
What this study cannot tell us
Current evidence on GLP-1 RA effects on bone health in humans with obesity is limited. Most robust bone data comes from animal models using doses higher than those used clinically. The review did not include fracture outcome data, which would be the most clinically meaningful endpoint. The bone effects may be confounded by weight loss itself rather than representing a direct drug effect.
How to read the evidence
This is a narrative review summarizing preclinical and clinical evidence. While it synthesizes a broad range of studies, it is not a systematic review or meta-analysis, and the human data on bone outcomes with GLP-1 RAs remains limited.
When this study was published
Published in 2025, this review covers literature through December 2024 and represents the most current synthesis of GLP-1 RA bone health data available.
The bigger picture
As GLP-1 receptor agonists expand from diabetes treatment into mainstream weight management, and as newer dual- and triple-receptor agonists (GLP-1/GIP/glucagon) emerge, understanding skeletal side effects becomes increasingly important. This is especially relevant for postmenopausal women and older adults who are already at elevated fracture risk.
Questions still open
- Do GLP-1 receptor agonists increase actual fracture risk in people using them for weight loss, or are the bone density changes clinically insignificant?
- How do newer dual- and triple-receptor agonists (GLP-1/GIP/glucagon) compare to pure GLP-1 agonists in their effects on bone?
- Should bone density monitoring be recommended for patients on long-term GLP-1 RA therapy for weight management?
Common questions
Do GLP-1 weight loss drugs weaken your bones?
Should I worry about bone health if I'm taking semaglutide or liraglutide for weight loss?
Read the original research
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 36(11), 2115-2126
Citation
Karam, Léa; Mabilleau, Guillaume; Paccou, Julien. (2025). Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 36(11), 2115-2126. https://doi.org/10.1007/s00198-025-07664-1